These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32332014)

  • 1. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma.
    Mendez F; Kadiyala P; Nunez FJ; Carney S; Nunez FM; Gauss JC; Ravindran R; Pawar S; Edwards M; Garcia-Fabiani MB; Haase S; Lowenstein PR; Castro MG
    Clin Cancer Res; 2020 Aug; 26(15):4080-4092. PubMed ID: 32332014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-stimulatory (TK/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas.
    Faisal SM; Mendez FM; Nunez F; Castro MG; Lowenstein PR
    Oncotarget; 2020 Dec; 11(50):4607-4612. PubMed ID: 33400737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
    Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
    Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model.
    Ali S; King GD; Curtin JF; Candolfi M; Xiong W; Liu C; Puntel M; Cheng Q; Prieto J; Ribas A; Kupiec-Weglinski J; van Rooijen N; Lassmann H; Lowenstein PR; Castro MG
    Cancer Res; 2005 Aug; 65(16):7194-204. PubMed ID: 16103070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
    Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
    Mineharu Y; Kamran N; Lowenstein PR; Castro MG
    Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
    Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
    Faisal SM; Castro MG; Lowenstein PR
    Mol Ther; 2023 Oct; 31(10):2839-2860. PubMed ID: 37574780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
    Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
    Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.
    Lowenstein PR; Castro MG
    Adv Pharmacol; 2016; 76():147-73. PubMed ID: 27288077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Mouse Model of Diffuse Intrinsic Pontine Glioma Initiated in Pax3-Expressing Cells.
    Misuraca KL; Hu G; Barton KL; Chung A; Becher OJ
    Neoplasia; 2016 Jan; 18(1):60-70. PubMed ID: 26806352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
    Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
    Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial.
    Umemura Y; Orringer D; Junck L; Varela ML; West MEJ; Faisal SM; Comba A; Heth J; Sagher O; Leung D; Mammoser A; Hervey-Jumper S; Zamler D; Yadav VN; Dunn P; Al-Holou W; Hollon T; Kim MM; Wahl DR; Camelo-Piragua S; Lieberman AP; Venneti S; McKeever P; Lawrence T; Kurokawa R; Sagher K; Altshuler D; Zhao L; Muraszko K; Castro MG; Lowenstein PR
    Lancet Oncol; 2023 Sep; 24(9):1042-1052. PubMed ID: 37657463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.